Results 221 to 230 of about 16,343,665 (315)

GSK-3 inactivation or depletion promotes β-cell replication via down regulation of the CDK inhibitor, p27 (Kip1) [PDF]

, 2011
Jeffrey Stein, Wieslawa Milewski, Manami Hara, Donald F. Steiner, Arunangsu Dey   +4 more
openalex   +1 more source

Update on preclinical models of cancer therapy‐related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio‐Oncology, and the ESC Working Group on Cellular Biology of the Heart

European Journal of Heart Failure, EarlyView.
New anticancer therapies with potential cardiovascular side effects are continuously being introduced into clinical practice, with new and often unexpected toxicities becoming apparent only after clinical introduction. These unknown toxicities should be identified and understood beforehand to better prepare patients and physicians, enabling the ...
Alessandra Ghigo, Pietro Ameri, Aarti Asnani, Edoardo Bertero, Rudolf A. de Boer, Dimitrios Farmakis, Arantxa González, Stephane Heymans, Borja Ibáñez, Teresa López‐Fernández, Alexander R. Lyon, Piero Pollesello, Amina Rakisheva, Konstantinos Stellos, Katrin Streckfuss‐Bömeke, Carlo Gabriele Tocchetti, Thomas Thum, Peter van der Meer, Eva Van Rooij, Piotr Ponikowski, Marco Metra, Giuseppe Rosano, Sophie Van Linthout   +22 more
wiley   +1 more source

Cardiac rhythm devices in heart failure with reduced ejection fraction – role, timing, and optimal use in contemporary practice. European Journal of Heart Failure expert consensus document

European Journal of Heart Failure, EarlyView.
Abstract Guidelines for management of heart failure with reduced ejection fraction (HFrEF) emphasize personalized care, patient engagement, and shared decision‐making. Medications and cardiac rhythm management (CRM) devices are recommended with a high level of evidence. However, there are significant disparities: patients who could benefit from devices
Biykem Bozkurt, Wilfried Mullens, Christophe Leclercq, Andrea M. Russo, Gianluigi Savarese, Michael Böhm, Loreena Hill, Koichiro Kinugawa, Naoki Sato, William T. Abraham, Antoni Bayes‐Genis, Alexandre Mebazaa, Giuseppe M.C. Rosano, Shelley Zieroth, Cecilia Linde, Javed Butler   +15 more
wiley   +1 more source

Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy

Redox Biology, 2017
A. Cuadrado, S. Kügler, I. Lastres-Becker   +2 more
semanticscholar   +1 more source

A GSK-3/TSC2/mTOR pathway regulates glucose uptake and GLUT1 glucose transporter expression

, 2008
Carolyn L. Buller, Robert D. Loberg, Ming‐Hui Fan, Qihong Zhu, James L. Park, Eileen Vesely, Ken Inoki, Kun‐Liang Guan, Frank C. Brosius   +8 more
openalex   +2 more sources

Finerenone, glycaemic status, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS‐HF trial

European Journal of Heart Failure, EarlyView.
Finerenone and glycaemic status in patients with heart failure with mildly reduced/preserved ejection fraction. CI, confidence interval; CV, cardiovascular; HF, heart failure; HR, hazard ratio; RR, rate ratio. Abstract Aims The efficacy and safety of the non‐steroidal mineralocorticoid receptor antagonist, finerenone, have not been examined in patients
Jawad H. Butt, Pardeep S. Jhund, Alasdair D. Henderson, Brian L. Claggett, Akshay S. Desai, Carolyn S.P. Lam, Meike Brinker, Patrick Schloemer, Prabhakar Viswanathan, Andrea Lage, Katja Rohwedder, Michele Senni, Sanjiv J. Shah, Adriaan A. Voors, Faiez Zannad, Bertram Pitt, Muthiah Vaduganathan, Scott D. Solomon, John J.V. McMurray   +18 more
wiley   +1 more source

Human colorectal cancer: upregulation of the adaptor protein Rai in TILs leads to cell dysfunction by sustaining GSK-3 activation and PD-1 expression. [PDF]

Cancer Immunol Immunother
Montecchi T, Nannini G, De Tommaso D, Cassioli C, Coppola F, Ringressi MN, Carraro F, Naldini A, Taddei A, Marotta G, Amedei A, Baldari CT, Ulivieri C.   +12 more
europepmc   +1 more source

GSK-3 Inhibition Is Cytotoxic in Glioma Stem Cells through Centrosome Destabilization and Enhances the Effect of Radiotherapy in Orthotopic Models. [PDF]

Cancers (Basel), 2021
Brüning-Richardson A, Shaw GC, Tams D, Brend T, Sanganee H, Barry ST, Hamm G, Goodwin RJA, Swales JG, King H, Steele L, Morton R, Widyadari A, Ward TA, Esteves F, Boissinot M, Mavria G, Droop A, Lawler SE, Short SC.   +19 more
europepmc   +1 more source

Selective loss of glycogen synthase kinase-3α in birds reveals distinct roles for GSK-3 isozymes in tau phosphorylation [PDF]

, 2011
Lina Alon, Shmuel Pietrokovski, Shay Barkan, Limor Avrahami, Oksana Kaidanovich‐Beilin, James R. Woodgett, Anat Barnea, Hagit Eldar-Finkelman   +7 more
openalex   +1 more source

Optimization of renin‐angiotensin‐aldosterone inhibitor therapies for evidence‐based indications: a call to action from the cardio‐kidney community

ESC Heart Failure, EarlyView.
Roberto Pecoits‐Filho, Michelle M.Y. Wong, Monica Moorthy, Debasish Banerjee, Suman Behera, Viviane Calice‐Silva, Mogamat‐Yazied Chothia, Gates B. Colbert, Martha Gulati, Charles A. Herzog, Fadi Jouhra, Edgar V. Lerma, Charu Malik, Kershaw V. Patel, Amina Rakisheva, Giuseppe M.C. Rosano, Priyanka Satish, Henry H.L. Wu, Angela Yee‐Moon Wang   +18 more
wiley   +1 more source